References
- Goate A, Chartier-Harlin M, Mullan M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991; 349(6311): 704–6
- Tanzi RE, Kovacs DM, Kim TW, et al. The gene defects responsible for familial Alzheimer's disease. Neurobiol Dis 1996; 3(3): 159–68
- Schellenberg GD, Bird TD, Wijsman EM, et al. Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14. Science 1992; 258(5082): 668–71
- Sherrington R, Rogaev EI, Liang Y, et al. Cloning of a gene bearing missense mutation in early-onset familial Alzheimer's disease. Nature 1995; 375(6534): 754–60
- Levy-Lahad E, Wasco W, Poorkaj P, et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 1995; 269(5226): 973–7
- Rogaev EI, Sherrington R, Rogaeva EA, et al. Familial Alzheimer's disease in kindreds with missense mutation in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 1995; 376(6543): 775–8
- Blacker D, Tanzi RE. The genetics of Alzheimer's disease: current status and future prospects. Arch Neurol 1998; 55(3): 294–6
- Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer's disease. Proc Natl Acad Sci USA 1993; 90(5): 1977–81
- Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993; 43(8): 1467–72
- Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997; 278(16): 1349–56
- Breitner JC, Wyse BW, Anthony JC, et al. APOE-epsilon 4 count predicts age when prevalence of AD increases, then declines: the Cache County Study. Neurology 1999; 53(2): 321–31
- Hyman BT, Gomez-Isla T, Briggs M, et al. Apolipoprotein E and cognitive change in an elderly population. Ann Neurol 1996; 40(1): 55–66
- Meyer MR, Tschanz JT, Norton MC, et al. APOE genotype predicts when—not whether—one is predisposed to develop Alzheimer disease. Nat Genet 1998; 19(4): 321–2
- Post SG, Whitehouse PJ, Binstock RH, et al. The clinical introduction of genetic testing for Alzheimer disease: an ethical perspective. JAMA 1997; 277(10): 832–6
- McConnell LM, Koenig BA, Greely HT, et al. Genetic testing and Alzheimer disease. Has the time come? Alzheimer Disease Working Group of the Stanford Program in Genomics, Ethics & Society. Nat Med 1998; 4(7): 757–9
- Consensus report of the Working Group on “Molecular and Biochemical Markers of Alzheimer's Disease. “The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute of Aging Working Group. Neurobiol Aging 1998; 19(2): 109–16
- Mayeux R, Saunders AM, Shea S, et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. N Engl J Med 1998; 338(8): 506–11
- Mayeux R. Evaluation and use of diagnostic tests in Alzheimer's disease. Neurobiol Aging 1998; 19(2): 139–43
- Petersen RC, Smith GE, Ivnik RJ, et al. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA 1995; 273(16): 1274–8
- Tierney MC, Szalai JP, Snow WG, et al. A prospective study of the clinical utility of ApoE genotype in the prediction of outcome in patients with memory impairment. Neurology 1996; 46(1): 149–54